LMAO..look at the chart.
The Company had net losses of $16.5 million and $50.0 million for the three and nine months ended September 30, 2021, respectively, net losses of $27.6 million and $74.3 million for the three and nine months ended September 30, 2020, respectively, and net cash used in operating activities of $40.0 million and $61.6 million for the nine months ended September 30, 2021 and 2020, respectively. To date, none of the Company’s drug candidates have been approved for sale, and therefore, the Company has not generated any revenue from contracts with customers and does not expect positive cash flows from operations in the foreseeable future.
luck is not going to save it and time draining the cash fast.
News 
Market Data 
Discover 
